CLOs on the Move

HeartBeam

www.heartbeam.com

 
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Simplify Medical

Simplify Medical has developed a cervical artificial disc that optimizes MRI imaging, the preferred and most accurate modality for evaluating soft tissue in the spine, while avoiding the ionizing radiation of CT scans. The Simplify Disc incorporates advanced materials to provide a metal free solution, optimum imaging capability, and kinematics.

Palomar Medical Technologies

Palomar Medical Technologies, Inc. is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Belmont Instruments

Belmont Instruments is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tri-Medical

Tri-Medical is a Lake Oswego, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insulet

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.